Sociedad Americana de Hirudoterapia

Microvascular Free-Flap Head and Neck Reconstruction: The Utility of the Modified Frailty Five-Item Index.

Research article published in Journal of reconstructive microsurgery (2024)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Research reportEnsayos clínicosOthman et al. · Journal of reconstructive microsurgery, 2024

Abstract

BACKGROUND:  Microvascular free tissue transfer is a common tool for the reconstruction of oncologic head and neck defects. Adequate preoperative assessment can aid in appropriate risk stratification and peri-operative optimization. The modified five-item frailty index (mFI-5) is a validated risk-assessment scale; however, its utility in head and neck free-flap reconstruction is unknown when compared with other common risk factors. METHODS:  A retrospective, single-institution chart review (2017-2020) was performed. Patient demographics, defect and repair characteristics, pre- and peri-operative factors, and flap outcomes were recorded. A high mFI-5 score was defined as greater than 2. The total score, as well as other patient factors, was correlated to postoperative flap complications. RESULTS:  A total of 214 patients were deemed appropriate for conclusion. The mean age was 63.9 ± 12.8 years. There were an even number of males (52.8%) and females (47.2%). A fifth of subjects (20.8%) underwent preoperative radiotherapy. There were 21 cases (9.8%) of complete flap loss. A total of 34 patients (29.4%) experienced any postoperative complication related to flap outcomes. An elevated mFI-5 was significantly associated with a higher overall rate of postoperative complications (39.7 vs. 29.4%, p < 0.019) and total flap loss (16.7% vs. 6.6%, p < 0.033). Preoperative radiation was found to be associated with an increased complication rate (p < 0.003). CONCLUSION:  The mFI-5 score may be a potentially significant tool in the risk stratification of patients undergoing head and neck free-flap reconstruction as opposed to commonly utilized risk factors. Preoperative radiotherapy is significantly associated with postoperative complications. Appropriate preoperative assessment may help tailor patient care preoperatively.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansMaleFemaleFree Tissue FlapsMiddle AgedRetrospective StudiesPlastic Surgery ProceduresHead and Neck NeoplasmsFrailtyPostoperative ComplicationsAgedRisk Assessment

Resumen

Microvascular free tissue transfer is a common tool for the reconstruction of oncologic head and neck defects. Adequate preoperative assessment can aid in appropriate risk stratification and peri-operative optimization.

Por qué esto importa para la hirudoterapia

Este estudio retrospectivo evaluó si el índice de fragilidad modificado de cinco ítems (mFI-5) predice las complicaciones postoperatorias en 214 pacientes sometidos a reconstrucción microvascular con colgajos libres de cabeza y cuello. Un mFI-5 elevado se asoció significativamente con mayores tasas de complicaciones globales y de pérdida total del colgajo. Esto es tangencialmente relevante para el dominio de ASH porque la reconstrucción con colgajos libres es un escenario clínico donde la terapia con sanguijuelas medicinales puede emplearse para controlar la congestión venosa y salvar colgajos comprometidos. No obstante, el resumen no menciona sanguijuelas, hirudoterapia ni el manejo de la congestión venosa. Por lo tanto, su relevancia es indirecta.

Citación

Microvascular Free-Flap Head and Neck Reconstruction: The Utility of the Modified Frailty Five-Item Index.

Othman et al. · Journal of reconstructive microsurgery, 2024

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.